The short answer
The FDA treats an alpha-amino acid polymer of 40 residues or fewer as a peptide, regulated as a drug. Anything longer is a protein, regulated as a biologic. Semaglutide is 31 residues, which places it on the drug side of that line.
Key facts
- Threshold
- 40 amino acids
- 40 or fewer
- Peptide, regulated as a drug
- More than 40
- Protein, regulated as a biologic
- Semaglutide
- 31 residues (a drug)
- IGF-1 LR3
- 83 residues (protein territory)
- Generic route for drugs
- ANDA, bioequivalence
- Generic route for biologics
- Biosimilar, higher burden
Why a line has to be drawn somewhere
Small molecules can be characterised completely: every atom, every bond, confirmed by analysis. Large proteins cannot, because their behaviour depends on folding and post-translational modification that no analytical method fully captures. Regulation treats these differently, and peptides sit between them, so a boundary is needed and any boundary will be somewhat arbitrary.
Why 40 is a reasonable place for it
Below roughly that length a molecule can generally be made by chemical synthesis and characterised to the atom. Above it, synthesis becomes progressively harder (coupling efficiency compounds, so a 40-mer at 99% per step finishes around 68% full-length before purification) and folding starts to matter. The number marks where full characterisation stops being achievable.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the classification changes
The route a generic takes. A drug generic files an ANDA and demonstrates bioequivalence, meaning that it delivers the same active ingredient at the same rate and extent. A biosimilar must demonstrate no clinically meaningful difference from the reference product, which usually requires comparative clinical work. The second is far slower and far more expensive.
The subtlety about manufacturing route
The FDA accepts that an ANDA applicant may show a proposed synthetic peptide is the same as the active ingredient in a previously approved peptide of recombinant DNA origin. So a generic can be chemically synthesised while the innovator was made recombinantly, and still be the same active ingredient. Sameness is judged on the molecule, not on how it was produced.
Where this catalogue falls either side of the line
Semaglutide at 31 residues and tirzepatide at 39 are both drugs. Retatrutide at 39 likewise. IGF-1 LR3 at 83 residues sits well past the threshold and would be handled as a biologic, which is consistent with it being a recombinant product with the impurity profile and folding concerns that come with one.
What none of this means for research material
Nothing supplied here holds any classification at all, because it holds no marketing authorisation. The drug-versus-biologic distinction governs how licensed medicines are approved and how their generics reach patients. It does not describe research chemicals, which sit outside that framework entirely.
Quick reference
| Compound | Residues | Classification |
|---|---|---|
| Semaglutide | 31 | Peptide (drug) |
| Tirzepatide | 39 | Peptide (drug) |
| Retatrutide | 39 | Peptide (drug) |
| IGF-1 LR3 | 83 | Protein territory (biologic) |
Frequently asked questions
Is Ozempic a biologic?
No. Semaglutide is 31 amino acids, and the FDA treats 40 or fewer as a peptide regulated as a drug.
Why does the classification matter?
Drug generics file an ANDA showing bioequivalence. Biosimilars must show no clinically meaningful difference from the reference, which is far slower and costlier.
Can a synthetic generic reference a recombinant innovator?
Yes. The FDA accepts that sameness can be demonstrated across manufacturing routes; it is judged on the molecule.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- When the Intended Effect Goes Too FarA 2026 systematic review describes gastroparesis as an under-recognised complication. It is the drug's own mechanism crossing into pathology.
- The Same Effect, Past the Point of BenefitSome adverse effects are unrelated toxicities. Others are the drug working too well. The two need different responses, and they get conflated.
- What the SUSTAIN Programme Data ShowedVilsbøll and colleagues evaluated retinopathy data across the SUSTAIN trials. The title places the HbA1c reduction between the drug and the risk.
- Why Fixing Glucose Quickly Can Make the Eye Worse FirstRapid improvement in glycaemic control is associated with transient worsening of retinopathy. It predates every modern diabetes drug.
- A Third Way an Adverse Effect Can AriseSome effects follow not from the drug but from what the drug achieves. Any intervention producing the same change as fast would produce them too.